Dye Based on Scorpion Venom Will Light Up Brain Cancer in Kids

Dye Based on Scorpion Venom Will Light Up Brain Cancer in Kids

A dye derived from scorpion venom that lights up cancer cells so surgeons can see — and remove — deadly brain tumors will be tested for the first time in children, Seattle experts said Thursday. Officials with the Food and Drug Administration (FDA) have expanded approval to enroll patients from infants to young adults in a clinical trial of the Blaze Bioscience drug BLZ-100, known as Tumor Paint. “I think it does have the potential to be revolutionary,” said Dr. Sarah Leary, a pediatric neuro-oncologist at Seattle Children’s who is the principal investigator for the trial.

About Seattle Children’s

Seattle Children’s mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children’s Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.

Ranked as one of the top children’s hospitals in the country by U.S. News & World Report, Seattle Children’s serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children’s hospital in the country. As one of the nation’s top five pediatric research centers, Seattle Children’s Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children’s Hospital and Research Foundation works with the Seattle Children’s Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research. Join Seattle Children’s bold initiative – It Starts With Yes: The Campaign for Seattle Children’s – to transform children’s health for generations to come.

For more information, visit or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.